Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial
Salmonella enterica serovar Typhi (S Typhi) is responsible for an estimated 20 million infections and 200 000 deaths each year in resource poor regions of the world. Capsular Vi-polysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogenic and can be used from infancy but there a...
主要な著者: | Jin, C, Gibani, M, Moore, M, Juel, H, Jones, E, Meiring, J, Harris, V, Gardner, J, Nebykova, A, Kerridge, S, Hill, J, Thomaides-Brears, H, Blohmke, C, Yu, l, Angus, B, Pollard, A |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Elsevier
2017
|
類似資料
-
Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV)
著者:: Voysey, M, 等
出版事項: (2018) -
Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh
著者:: Khanam, F, 等
出版事項: (2023) -
Salmonella typhi bactericidal antibodies reduce disease severity but do not protect against typhoid fever in a controlled human infection model
著者:: Juel, H, 等
出版事項: (2018) -
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial
著者:: Qadri, F, 等
出版事項: (2021) -
Antibodies to the Vi capsule of Salmonella Typhi in the serum of typhoid patients and healthy control subjects from a typhoid endemic region.
著者:: House, D, 等
出版事項: (2008)